Electrocore (ECOR)

$5.94

-0.06

(-1%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $5.94
    $6.24
    $5.94
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.81%

    Upside

    4.81%

    downward going graph
  • $4.90
    $8.08
    $5.94
    downward going graph

    17.51%

    Downside

    52 Weeks Volatility :39.36%

    Upside

    26.49%

    downward going graph

Returns

PeriodElectrocoreIndex (Russel 2000)
3 Months
-9.31%
0.0%
6 Months
-12.77%
0.0%
1 Year
-0.83%
0.0%
3 Years
-61.18%
-22.3%

Highlights

Market Capitalization
38.7M
Book Value
$1.78
Earnings Per Share (EPS)
-2.05
Wall Street Target Price
23.1
Profit Margin
-66.84%
Operating Margin TTM
-42.21%
Return On Assets TTM
-49.18%
Return On Equity TTM
-153.49%
Revenue TTM
21.3M
Revenue Per Share TTM
3.25
Quarterly Revenue Growth YOY
72.89999999999999%
Gross Profit TTM
7.2M
EBITDA
-13.5M
Diluted Eps TTM
-2.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.47
EPS Estimate Next Year
-0.55
EPS Estimate Current Quarter
-0.44
EPS Estimate Next Quarter
-0.35

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Electrocore(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 288.89%

Current $5.94
Target $23.10

Technicals Summary

Sell

Neutral

Buy

Electrocore is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Electrocore
Electrocore
-2.62%
-12.77%
-0.83%
-61.18%
-86.3%
Stryker Corporation
Stryker Corporation
12.3%
0.36%
24.19%
28.8%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
10.6%
20.32%
51.42%
80.93%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
9.4%
-28.78%
-12.2%
-45.23%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.57%
-5.84%
13.1%
-11.32%
35.19%
Medtronic Plc
Medtronic Plc
10.85%
5.57%
12.46%
-33.2%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Electrocore
Electrocore
NA
NA
NA
-1.47
-1.53
-0.49
NA
1.78
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Electrocore
Electrocore
Buy
$38.7M
-86.3%
NA
-66.84%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Electrocore

  • Increasing Revenue

    Revenue is up for the last 8 quarters, 1.97M → 6.13M (in $), with an average increase of 14.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 6 quarters, -5.86M → -2.65M (in $), with an average increase of 17.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 52.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 142.1%

Institutional Holdings

  • Awm Investment Company Inc

    8.40%

  • Vanguard Group Inc

    2.61%

  • International Assets Investment Management, LLC

    1.05%

  • Renaissance Technologies Corp

    1.03%

  • Geode Capital Management, LLC

    0.82%

  • Sontag Advisory LLC

    0.74%

Company Information

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.

Organization
Electrocore
Employees
68
CEO
Mr. Daniel S. Goldberger
Industry
Health Technology

Discover More

FAQs